Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Botulinum neurotoxin Light Chain/A1 uses fast synaptic vesicle cycling to cleave plasma membrane bound SNAP-25.

Communications biology·2025

Same author

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.

International journal of molecular sciences·2024

Same author

Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.

Vaccines·2023

Same author

Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain.

International journal of molecular sciences·2023

Same author

How Botulinum Neurotoxin Light Chain A1 Maintains Stable Association with the Intracellular Neuronal Plasma Membrane.

Toxins·2022

Same author

Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein.

Vaccine·2022

Same journal

Correction for Nishimori et al., “Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis”

Clinical and vaccine immunology : CVI·2018

Same journal

Effect of Breastfeeding and Additional Household Children on Cytomegalovirus Seroprevalence among U.S. Children 1 to 5 Years of Age.

Clinical and vaccine immunology : CVI·2017

Same journal

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Clinical and vaccine immunology : CVI·2017

Same journal

The Legacy of CVI.

Clinical and vaccine immunology : CVI·2017

Same journal

Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.

Clinical and vaccine immunology : CVI·2017

Same journal

Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Clinical and vaccine immunology : CVI·2017

See all related articles

Search research articles

Home
Protein Structure Facilitates High-resolution Immunological Mapping.

Home
Protein Structure Facilitates High-resolution Immunological Mapping.

Related Experiment Video

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

Protein Structure Facilitates High-Resolution Immunological Mapping.

Madison Zuverink¹, Joseph T Barbieri²

¹Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Clinical and Vaccine Immunology : CVI

|October 20, 2017

View abstract on PubMed

Summary

This summary is machine-generated.

Developing next-generation vaccines and therapies against select agents like ricin and botulinum toxin is crucial. Structure-based approaches accelerate the creation of countermeasures for rapid biothreat response.

Keywords:

RTA RVEc RiVax antibodies botulinum toxin mass spectrometry ricin

More Related Videos

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

Published on: May 16, 2017

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Published on: May 29, 2021

Related Experiment Videos

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

Published on: May 16, 2017

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Published on: May 29, 2021

Area of Science:

Biodefense
Toxinology
Vaccinology

Background:

Select agents (SA) present significant regulatory and developmental challenges for medical countermeasures.
Toxin-mediated diseases require specific guidelines for SA use, development oversight, and model validation.
Existing countermeasures may not be sufficient for emerging biothreats.

Purpose of the Study:

To discuss next-generation vaccines and therapies against regulated SA toxins.
To highlight the role of structure-based approaches in developing rapid countermeasures.
To inform strategies for responding to future biothreats.

Main Methods:

Review of current regulatory frameworks for SA countermeasure development.
Analysis of structure-based design principles for toxin neutralization.

Discussion of advancements in vaccine and therapy development against ricin and botulinum toxin.

Main Results:

Structure-based approaches offer a pathway for accelerated development of novel vaccines and therapies.
Next-generation countermeasures can be designed to target specific toxin neutralization mechanisms.
Regulatory pathways can be adapted to facilitate rapid response to biothreats.

Conclusions:

Next-generation vaccines and therapies against SA toxins are essential for biodefense.
Structure-based design is a key strategy for rapid development of effective countermeasures.
Integrated regulatory and scientific approaches are vital for addressing future biothreats.